KASL clinical practice guidelines: management of chronic hepatitis B.
出版信息
Clin Mol Hepatol. 2016 Mar;22(1):18-75. doi: 10.3350/cmh.2016.22.1.18. Epub 2016 Mar 28.
Abstract
摘要
相似文献
1
KASL clinical practice guidelines: management of chronic hepatitis B.KASL临床实践指南：慢性乙型肝炎的管理
Clin Mol Hepatol. 2016 Mar;22(1):18-75. doi: 10.3350/cmh.2016.22.1.18. Epub 2016 Mar 28.
2
KASL Clinical Practice Guidelines: Management of chronic hepatitis B.韩国肝病学会临床实践指南：慢性乙型肝炎的管理。
Clin Mol Hepatol. 2012 Jun;18(2):109-62. doi: 10.3350/cmh.2012.18.2.109. Epub 2012 Jun 26.
3
KASL clinical practice guidelines for management of chronic hepatitis B.《慢性乙型肝炎管理的KASL临床实践指南》
Clin Mol Hepatol. 2019 Jun;25(2):93-159. doi: 10.3350/cmh.2019.1002. Epub 2019 Jun 12.
4
[Chronic hepatitis B].[慢性乙型肝炎]
Dtsch Med Wochenschr. 2008 Jan;133(4):135-8. doi: 10.1055/s-2008-1017488.
5
When (and When Not) to Treat Patients With HBV Infection.何时（以及何时不）治疗乙肝病毒感染患者。
Clin Gastroenterol Hepatol. 2019 Dec;17(13):2644-2647. doi: 10.1016/j.cgh.2019.05.039. Epub 2019 May 30.
6
[New insight for HBV DNA and HBsAg quantitation during antiviral therapy in patients with chronic hepatitis B].[慢性乙型肝炎患者抗病毒治疗期间HBV DNA和HBsAg定量的新见解]
Korean J Gastroenterol. 2011 Mar;57(3):144-9. doi: 10.4166/kjg.2011.57.3.144.
7
2018 Korean Association for the Study of the Liver (KASL) Clinical Practice Guidelines of Chronic Hepatitis B: What's Different?2018年韩国肝脏研究协会（KASL）慢性乙型肝炎临床实践指南：有何不同？
Korean J Gastroenterol. 2019 Mar 25;73(3):132-140. doi: 10.4166/kjg.2019.73.3.132.
8
Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients.拉米夫定联合阿德福韦酯治疗乙型肝炎相关肝细胞癌患者的拉米夫定耐药。
Clin Mol Hepatol. 2013 Sep;19(3):273-9. doi: 10.3350/cmh.2013.19.3.273. Epub 2013 Sep 30.
9
Emerging therapies of hepatitis B and C.乙型和丙型肝炎的新兴疗法。
J Gastroenterol Hepatol. 2002 Dec;17 Suppl:S471-81. doi: 10.1046/j.1440-1746.17.s4.13.x.
10
New diagnostic tools of hepatitis virus-related liver diseases. Preface.肝炎病毒相关性肝病的新诊断工具。前言。
Intervirology. 2008;51 Suppl 1:1-2. doi: 10.1159/000122591. Epub 2008 Jun 10.
引用本文的文献
1
Similar recurrence after curative treatment of HBV-related HCC, regardless of HBV replication activity.HBV 相关 HCC 经治愈性治疗后，无论 HBV 复制活性如何，均有相似的复发。
PLoS One. 2024 Aug 26;19(8):e0307712. doi: 10.1371/journal.pone.0307712. eCollection 2024.
2
Non-Invasive Monitoring of the Impact of Low-Level Viremia on Liver Fibrosis in Treated Chronic Hepatitis B Patients.低水平病毒血症对慢性乙型肝炎治疗患者肝纤维化影响的无创监测
Infect Drug Resist. 2024 Jul 3;17:2751-2758. doi: 10.2147/IDR.S463843. eCollection 2024.
3
Statin use and the risk of hepatocellular carcinoma among patients with chronic hepatitis B: an emulated target trial using longitudinal nationwide population cohort data.他汀类药物的使用与慢性乙型肝炎患者肝细胞癌风险的关系：一项使用纵向全国人群队列数据模拟目标试验。
BMC Gastroenterol. 2023 Oct 25;23(1):366. doi: 10.1186/s12876-023-02996-w.
4
Prediction of Post-resection Prognosis Using the ADV Score for Huge Hepatocellular Carcinomas ≥13 cm.使用ADV评分预测直径≥13cm的巨大肝细胞癌切除术后的预后
J Liver Cancer. 2021 Mar;21(1):45-57. doi: 10.17998/jlc.21.1.45. Epub 2021 Mar 31.
5
Liquid biopsy for early detection and therapeutic monitoring of hepatocellular carcinoma.用于肝细胞癌早期检测和治疗监测的液体活检
J Liver Cancer. 2022 Sep;22(2):103-114. doi: 10.17998/jlc.2022.09.08. Epub 2022 Sep 22.
6
Adding MRI as a Surveillance Test for Hepatocellular Carcinoma in Patients with Liver Cirrhosis Can Improve Prognosis.将磁共振成像（MRI）作为肝硬化患者肝细胞癌的监测检查手段可改善预后。
Biomedicines. 2023 Jan 27;11(2):382. doi: 10.3390/biomedicines11020382.
7
Expression Patterns of Tumor Markers in Liver Transplant Recipients Showing Complete Pathological Response of Hepatocellular Carcinoma.肝细胞癌完全病理缓解的肝移植受者中肿瘤标志物的表达模式
J Clin Med. 2022 Oct 6;11(19):5897. doi: 10.3390/jcm11195897.
8
Risk stratification of primary liver cancer.原发性肝癌的风险分层
World J Clin Cases. 2022 Sep 16;10(26):9545-9549. doi: 10.12998/wjcc.v10.i26.9545.
9
Hepatitis B virus S gene therapy with 10-23 DNAzyme delivered by chitosan--stearic acid micelles.壳聚糖-硬脂酸胶束递送10-23脱氧核酶的乙肝病毒S基因治疗
RSC Adv. 2019 May 15;9(27):15196-15204. doi: 10.1039/c9ra00330d. eCollection 2019 May 14.
10
KASL clinical practice guidelines for management of chronic hepatitis B.《慢性乙型肝炎管理的KASL临床实践指南》
Clin Mol Hepatol. 2022 Apr;28(2):276-331. doi: 10.3350/cmh.2022.0084. Epub 2022 Apr 1.
本文引用的文献
1
Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen-positive chronic hepatitis B.恩替卡韦与安慰剂治疗乙型肝炎 e 抗原阳性慢性乙型肝炎儿童的随机、对照试验。
Hepatology. 2016 Feb;63(2):377-87. doi: 10.1002/hep.28015. Epub 2015 Oct 16.
2
Optimal management of hepatitis B virus infection - EASL Special Conference.乙型肝炎病毒感染的最佳管理-EASL 特别会议。
J Hepatol. 2015 Nov;63(5):1238-53. doi: 10.1016/j.jhep.2015.06.026. Epub 2015 Jul 3.
3
Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load.慢性乙型肝炎病毒感染代偿性肝硬化患者低病毒载量与肝细胞癌风险。
Hepatology. 2015 Sep;62(3):694-701. doi: 10.1002/hep.27889. Epub 2015 Jul 3.
4
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.阿德福韦耐药慢性乙型肝炎患者多药耐药时单用替诺福韦与替诺福韦联合恩替卡韦治疗的随机试验结果。
Gut. 2016 Jun;65(6):1042-51. doi: 10.1136/gutjnl-2014-308435. Epub 2015 Mar 23.
5
Accuracy of transient elastography in assessing liver fibrosis in chronic viral hepatitis: A multicentre, retrospective study.瞬时弹性成像评估慢性病毒性肝炎肝纤维化的准确性：一项多中心回顾性研究。
Liver Int. 2015 Oct;35(10):2246-55. doi: 10.1111/liv.12808. Epub 2015 Feb 26.
6
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.替诺福韦单药治疗与替诺福韦和恩替卡韦联合治疗对多种药物耐药的慢性乙型肝炎患者：一项随机试验的结果。
Gut. 2016 May;65(5):852-60. doi: 10.1136/gutjnl-2014-308353. Epub 2015 Jan 16.
7
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection.替诺福韦酯治疗慢性乙型肝炎病毒感染的七年疗效与安全性
Dig Dis Sci. 2015 May;60(5):1457-64. doi: 10.1007/s10620-014-3486-7. Epub 2014 Dec 23.
8
Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling.长期使用替诺福韦治疗亚裔美国慢性乙型肝炎患者与肾脏磷酸盐处理异常有关。
Dig Dis Sci. 2015 Feb;60(2):566-72. doi: 10.1007/s10620-014-3363-4. Epub 2014 Sep 20.
9
Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study.BE-LOW 研究中恩替卡韦或恩替卡韦联合替诺福韦治疗初治慢性乙型肝炎患者的 HBsAg 定量。
J Hepatol. 2015 Jan;62(1):56-63. doi: 10.1016/j.jhep.2014.08.031. Epub 2014 Aug 28.
10
Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk?替诺福韦治疗的慢性乙型肝炎患者的骨矿物质密度评估：骨折风险评估工具能否识别出风险最高的患者？
J Infect Dis. 2015 Feb 1;211(3):374-82. doi: 10.1093/infdis/jiu471. Epub 2014 Aug 25.
Zotero 插件